MediPharm Announces Voting Results from the 2025 Annual and Special Meeting of Shareholders
There were 146 Shareholders represented virtually or by proxy at the Meeting holding an aggregate of 210,726,733 common shares, representing 50.76% of MediPharm's total issued and outstanding common shares as at the record date for the Meeting. As the Meeting was held virtually, all resolutions were passed by way of ballot.
Shareholders approved the resolution to fix the number of directors at seven, approved the resolution appointing MNP LLP as auditors, elected all seven management director nominees and approved the resolution relating to unallocated awards under the Company's equity incentive plan. Complete voting results for each of the matters presented at the Meeting are provided below.
Board Changes
The Company welcomes new directors Emily Jameson and John Medland to the Board. Michael Bumby did not stand for re-election as a director at the Meeting. The Board thanks Mr. Bumby for his invaluable contributions. He was instrumental in the transformative VIVO acquisition which has helped set MediPharm up for its next phase of growth.
Complete Voting Results from the Meeting
1. Setting the Number of Directors at Seven
The special resolution to fix the number of directors of the Company at seven (7) was approved by Shareholders. Voting results are as set out below:
Votes For
Votes Against
#
%
#
%
159,023,437
75.46
51,703,294
24.54
2. Election of Directors
Each of the Company's nominees were elected as directors of MediPharm for the ensuing year or until their successors are elected or appointed. Voting results for each director nominee are as set out below:
Nominee
#
Management Nominees
Chris Halyk
144,007,422
Emily Jameson
144,289,930
John Medland
144,182,233
David Pidduck
142,961,350
Shelley Potts
144,156,682
Keith Strachan
140,531,927
Chris Taves
143,500,811
Dissident Nominees
John Fowler
51,801,045
Alan D. Lewis
51,681,657
David Lontini
51,611,107
Demetrios Mallios
51,531,594
Regan McGee
51,634,357
Scott Walters
51,677,144
3. Appointment of Auditor
MNP LLP, Chartered Professional Accountants, was appointed as auditor of MediPharm until the next annual meeting of the holders of the Shareholders at remuneration to be fixed by the directors. Voting results are as set out below:
Votes For
Votes Withheld
#
%
#
%
191,303,393
90.78
19,423,340
9.22
4. Approval of Unallocated Awards Under Equity Incentive Plan
A resolution to approve, among other things, the unallocated awards available under the Company's equity incentive plan was approved by Shareholders. Voting results are as set out below:
Votes For
Votes Against
#
%
#
%
101,750,700
50.14%
101,162,710
49.86
About MediPharm Labs
Founded in 2015, MediPharm Labs specializes in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates, active pharmaceutical ingredients (API) and advanced derivative products utilizing a Good Manufacturing Practices certified facility with ISO standard-built clean rooms. MediPharm Labs has invested in an expert, research driven team, state-of-the-art technology, downstream purification methodologies and purpose-built facilities for delivery of pure, trusted and precision-dosed cannabis products for its customers. MediPharm Labs develops, formulates, processes, packages and distributes cannabis and advanced cannabinoid-based products to domestic and international medical markets.
In 2021, MediPharm Labs received a Pharmaceutical Drug Establishment License from Health Canada, becoming the only company in North America to hold a commercial-scale domestic Good Manufacturing Practices License for the extraction of multiple natural cannabinoids. This GMP license was the first step in the Company's current foreign drug manufacturing site registration with the US FDA.
In 2023, MediPharm acquired VIVO Cannabis Inc., which expanded MediPharm's reach to medical patients in Canada via Canna Farms medical ecommerce platform, and in Australia and Germany through Beacon Medical Australia PTY Ltd. and Beacon Medical Germany GMBH. This acquisition also included Harvest Medical Clinics in Canada which provides medical cannabis patients with Physician consultations for medical cannabis education and prescriptions.
The Company carries out its operations in compliance with all applicable laws in the countries in which it operates.
Investor Contact:
MediPharm Labs Investor RelationsTelephone: +1 416.913.7425Email: investors@medipharmlabs.com
Media Contact:
John VincicOakstrom Advisors+1 (647) 402-6375john@oakstrom.com
Cautionary Note Regarding Forward-Looking Information:
This news release contains 'forward-looking information' and 'forward-looking statements' (collectively, 'forward-looking statements') within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as 'expects', or 'does not expect', 'is expected', 'anticipates' or 'does not anticipate', 'plans', 'budget', 'scheduled', 'forecasts', 'estimates', 'believes' or 'intends' or variations of such words and phrases or stating that certain actions, events or results 'may' or 'could', 'would', 'might' or 'will' be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to: general business, economic, competitive, political and social uncertainties; the inability of MediPharm to obtain adequate financing; the delay or failure to receive regulatory approvals; and other factors discussed in MediPharm's continuous disclosure filings, available on the SEDAR+ website at www.sedarplus.ca. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on the forward-looking statements and information contained in this news release. Except as required by law, MediPharm assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
XRP Gets Its Own Treasury Company: Look Who's Building A $20 Million XRP Reserve
Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below. Nature's Miracle Holding Inc. (OTCQB:NMHI), a publicly listed vertical farming technology firm, on Wednesday announced plans to allocate up to $20 million towards a new corporate treasury strategy centered around Ripple's (CRYPTO: XRP). The company stated that it will use proceeds from a recently approved equity financing arrangement to fund the purchase of XRP tokens, with aims to treat the cryptocurrency as a long-term strategic reserve. The decision makes Nature's Miracle one of the first publicly traded non-financial companies to adopt XRP, currently the third-largest cryptocurrency by market capitalization, as a treasury asset. Don't Miss: 7,000+ investors have joined Timeplast's mission to eliminate microplastics— This AI-Powered Trading Platform Has 5,000+ Users, 27 Pending Patents, and a $43.97M Valuation — You Can Become an Investor for Just $500.25 The company also plans to engage with staking opportunities and broader participation in the Ripple ecosystem. According to the release, the funding will initially come from capital raised under a registration statement on Form S-1 declared effective by the U.S. Securities and Exchange Commission. Further XRP purchases may be financed through a mix of equity issuances, structured financing, and strategic placements. CEO James Li attributed the move to increased regulatory clarity following the recent passage of the GENIUS Act, signed into law by President Donald Trump on July 18, which has encouraged broader corporate participation in the digital asset space. 'We see the huge potential of XRP as it improves the speed and reduces the cost of cross-border payments,' Li said. Nature's Miracle joins a growing list of companies engaged with XRP. Financial institutions such as Banco Santander (NYSE:SAN) and American Express (NYSE:AXP) have already incorporated Ripple's payment technologies into their operations. In 2023, Japan's SBI Holdings announced the use of XRP in its internal treasury operations, while other blockchain-native firms have used XRP for cross-border liquidity and remittance flows. Read Next: $100k+ in investable assets? Match with a fiduciary advisor for free to learn how you can maximize your retirement and save on taxes – no cost, no obligation. If there was a new fund backed by Jeff Bezos offering a 7-9% target yield with monthly dividends would you invest in it? Image: Shutterstock This article XRP Gets Its Own Treasury Company: Look Who's Building A $20 Million XRP Reserve originally appeared on Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Hamilton Spectator
2 hours ago
- Hamilton Spectator
Imperial Provides Update on Fall of Ground Incident and Reports Production for 2025 Second Quarter at Red Chris Mine
VANCOUVER, British Columbia, July 24, 2025 (GLOBE NEWSWIRE) — Imperial Metals Corporation ('Imperial' or the 'Company') (TSX:III) provides an update on the two fall of ground incidents at the 30% owned Red Chris mine in northwest British Columbia. In coordination with industry partners, mine operator Newmont has deployed specialized drones to assess the geotechnical conditions underground. The debris blocking access to the underground area is estimated to be approximately 20 to 30 metres long and 7 to 8 metres high. The area of the refuge chambers is not in the same area as the fall of ground and is understood to be stable and well-ventilated. Newmont has commenced the use of a remote-controlled scoop, that was transported from the nearby Brucejack mine site, to begin removing debris and restore access beyond the incident site. Teams are restoring the specialized communication system (leaky feeder system) in attempts to re-establish communication with the workers. The workers are understood to be sheltering in a MineARC refuge chamber designed to support 16 people. Additional refuge chambers are also available nearby and accessible if required. Production at Red Chris mine has been paused to allow full focus on rescue efforts and re-establishing communication. Imperial also reports quarterly copper and gold production for the period ending June 30, 2025 from Red Chris mine. Red Chris mine production (100%) for the second quarter of 2025 was 23.479 million pounds copper and 22,624 ounces gold compared to 20.731 million pounds copper and 12,531 ounces gold during the second quarter of 2024. In the second quarter of 2025, Red Chris mine copper production was up 13% compared to the second quarter of 2024. The increase in copper production was a result of a 17% increase in copper grade (0.547% vs 0.466%), offset by a small decrease in throughput. Gold production in the second quarter of 2025 was up 81% from the second quarter of 2024 as result of the increased gold grades and better recovery, offset by slightly lower throughput. For the first six months of 2025, copper production was up 25% compared to the same period last year on higher copper grades and gold production was up 101% on higher gold grades and better recovery. The Red Chris Block Cave Feasibility Study is advancing as are permitting activities and early-stage underground development work and other work to support the underground block cave project. The total development completed to June 30, 2025, was approximately 11,727 metres, completed on both the Nagha and conveyor declines. The technical and scientific information related to the Company's mineral projects has been reviewed and approved by Brian Kynoch, President of Imperial, the designated Qualified Person as defined by National Instrument 43-101. About Imperial Imperial is a Vancouver based exploration, mine development and operating company with holdings that include the Mount Polley mine (100%), the Huckleberry mine (100%), and the Red Chris mine (30%). Imperial also holds a portfolio of 23 exploration properties in British Columbia. Company Contacts Brian Kynoch | President | 604.669.8959 Darb S. Dhillon | Chief Financial Officer | 604.669.8959 Cautionary Note Regarding Forward-Looking Statements Certain information contained in this news release are not statements of historical fact and are 'forward-looking' statements. Forward-looking statements relate to future events or future performance and reflect Imperial management's expectations or beliefs regarding future events and include, but are not limited to, statements regarding the ongoing work to advance the Red Chris Block Cave Feasibility Study, permitting activities and early-stage underground development work and other work to support the underground block cave project. In certain cases, forward-looking statements can be identified by the use of words such as 'plans', 'expects' or 'does not expect', 'is expected', 'outlook', 'budget', 'scheduled', 'estimates', 'forecasts', 'intends', 'anticipates' or 'does not anticipate', or 'believes', or variations of such words and phrases or statements that certain actions, events or results 'may', 'could', 'would', 'might' or 'will be taken', 'occur' or 'be achieved' or the negative of these terms or comparable terminology. By their very nature forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Imperial to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. In making the forward-looking statements in this news release, Imperial has applied certain factors and assumptions that are based on information currently available to Imperial as well as Imperial's current beliefs and assumptions. These factors and assumptions and beliefs and assumptions include, the risk factors detailed in Imperial's current annual information form and from time to time in Imperial's interim and annual financial statements and management's discussion and analysis of those statements, all of which are filed and available for review on SEDAR+ at . Although Imperial has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended, many of which are beyond Imperial's ability to control or predict. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and all forward-looking statements in this news release are qualified by these cautionary statements.
Yahoo
2 hours ago
- Yahoo
TFSA Fortune: How 1 Technology Stock Could Secure Your Financial Future
Written by Brian Paradza, CFA at The Motley Fool Canada Imagine turning a $7,000 investment into a staggering $2.5 million position, entirely within the tax-free haven of your TFSA. That's the remarkable reality for investors in Constellation Software (TSX:CSU) stock over the past two decades – a mind-boggling total return exceeding 36,000%. While replicating that exact feat might be a tall order, a spun-off company following the same powerful blueprint strategy could be poised for significant long-term growth, making it a compelling candidate for your own TFSA. That TSX technology stock is (TSXV:TOI), and it's grabbing serious attention this week as the top performer on the TSX's Top Tech 50 list. isn't just riding a growth wave; it's actively building one. Much like its former parent Constellation Software, Topicus focuses on acquiring, managing, and building specialized vertical market software businesses – essential software solutions tailored for specific industries. While Constellation conquered North America, is methodically applying the same winning strategy across diverse markets in Europe. Canadian investors seeking long-term growth within their TFSA may find Topicus's focused approach appealing. Why stock deserves a place in your TFSA The tech stock's early results are promising. spun off from Constellation in early 2021, and early investors are already sitting on gains nearing 200%. More importantly, the underlying business is firing on all cylinders. first-quarter 2025 results showcased impressive momentum. Revenue surged 16% year-over-year to €355.6 million (about $569 million CAD), driven by strategic acquisitions and a solid 4% organic growth rate. Earnings per share jumped an even more impressive 36.4% to €0.30. But the real story, the fuel powering growth engine, is its free cash flow (FCF). This crucial metric represents the cash a company generates after accounting for operating expenses and capital expenditures — the actual cash-based profit available for reinvestment, dividends, or debt repayment. Topicus generated a staggering €271.4 million in cash flow from operations during the first quarter, leading to free cash flow of €161.7 million ($258.8 million CAD), a 21% year-over-year increase. This torrent of free cash flow is the lifeblood of growth strategy. It allows the TSX tech stock to aggressively pursue acquisitions without constantly needing external financing. For example, during the first quarter, completed acquisitions totaling €39.4 million ($63 million CAD). With quarterly FCF exceeding €161 million, Topicus has the capacity to significantly ramp up its deal-making. It could could have quadrupled its acquisition spend just from the first quarter FCF alone! This self-sustaining model is precisely how Constellation built its empire. Long-term oriented TFSA investors may wish to check stock out before fully deploying their $7,000 contribution room for 2025. TOI stock valuation and the Constellation blueprint To be clear, TOI stock carries a premium valuation. Its forward price-to-earnings ratio (P/E) sits around 69, higher than the industry average of 52. However, looking solely at earnings misses the bigger picture fueled by cash. When you consider its phenomenal cash generation, stock looks far more reasonably priced. Its price-to-free-cash-flow (P/FCF) multiple is 38.6, significantly cheaper than the North American industry average of 66. Similarly, its enterprise value-to-free-cash-flow (EV/FCF) multiple of 25 compares very favourably to the industry average of 56. The big question for TFSA investors is: Can replicate the phenomenal success of Constellation Software stock? ^TSX data by YCharts The potential for stock to widely outperform the TSX is certainly there. Topicus still operates under Constellation's guidance, and it is using the exact same proven playbook. The company's core strategy of acquiring essential, niche software businesses is time-tested. Chances of outright failure seem low. However, tempering expectations is prudent. Europe presents different market dynamics than North America. More crucially, the timing is different. Constellation began its acquisition spree 30 years ago in 1995 and survived the aftermath of the dot-com bust, finding bargains when tech valuations were depressed. Topicus is executing its strategy in the artificial intelligence (AI) era, where software valuations are generally higher. While the strategy is sound, expecting an identical 36,000% return over the next 20 years is potentially unrealistic. TFSA investor takeaway stock represents a fascinating opportunity for TFSA investors seeking long-term, tax-free compound growth. It possesses a powerful engine: the proven Constellation Software acquisition strategy, now focused on the European market, and fueled by rapidly growing, substantial free cash flow. This internally generated cash allows the technology stock to aggressively fund its own growth, creating a potentially powerful compounding effect within your TFSA. The post TFSA Fortune: How 1 Technology Stock Could Secure Your Financial Future appeared first on The Motley Fool Canada. Should you invest $1,000 in Constellation Software right now? Before you buy stock in Constellation Software, consider this: The Motley Fool Stock Advisor Canada analyst team just identified what they believe are the Top Stocks for 2025 and Beyond for investors to buy now… and Constellation Software wasn't one of them. The Top Stocks that made the cut could potentially produce monster returns in the coming years. Consider MercadoLibre, which we first recommended on January 8, 2014 ... if you invested $1,000 in the 'eBay of Latin America' at the time of our recommendation, you'd have $24,927.94!* Stock Advisor Canada provides investors with an easy-to-follow blueprint for success, including guidance on building a portfolio, regular updates from analysts, and two new stock picks each month – one from Canada and one from the U.S. The Stock Advisor Canada service has outperformed the return of S&P/TSX Composite Index by 30 percentage points since 2013*. See the Top Stocks * Returns as of 6/23/25 More reading 10 Stocks Every Canadian Should Own in 2025 3 Canadian Companies Powering the AI Revolution A Commonsense Cash Back Credit Card We Love Fool contributor Brian Paradza has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends The Motley Fool recommends Constellation Software. The Motley Fool has a disclosure policy. 2025 Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
